SCHEMBL3669271

SCHEMBL3669271

C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC(=O)[C@@H]2O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.70
SHBG P04278 7/20 0.70
HSD17B10 Q99714 5/20 0.70
SERPINA6 P08185 5/20 0.70
TSHR P16473 5/20 0.70
CYP3A4 P08684 5/20 0.70
MAPK1 P28482 5/20 0.70
CYP19A1 P11511 4/20 0.70
SNCA P37840 4/20 0.70
NR3C1 P04150 4/20 0.70
PGR P06401 4/20 0.70
MAPT P10636 4/20 0.70
AR P10275 3/20 0.70
GPBAR1 Q8TDU6 3/20 0.70
SIGMAR1 Q99720 3/20 0.70
CACNA1C Q13936 2/20 0.70
CYP51A1 Q16850 2/20 0.70
OR51E2 Q9H255 1/20 0.70
SMN1; SMN2 Q16637 5/20 0.63
ALDH1A1 P00352 5/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13753024 1.00 LMNA (0.70) LMNASHBGHSD17B10SERPINA6TSHR
SCHEMBL4105501 1.00 LMNA (0.70) LMNASHBGHSD17B10SERPINA6TSHR
SCHEMBL3671789 0.85 LMNA (0.69) LMNASHBGHSD17B10SERPINA6TSHR
SCHEMBL10892406 0.83 LMNA (0.61) LMNASHBGHSD17B10SERPINA6TSHR
SCHEMBL3672472 0.83 CYP3A4 (0.63) LMNASHBGHSD17B10SERPINA6TSHR
SCHEMBL3672474 0.83 CYP3A4 (0.63) LMNASHBGHSD17B10SERPINA6TSHR
SCHEMBL15011284 0.83 CYP3A4 (0.63) LMNASHBGHSD17B10SERPINA6TSHR
Epitestosterone SCHEMBL12367194 0.82 AR (1.00) LMNASHBGHSD17B10SERPINA6TSHR
Epitestosterone SCHEMBL22704809 0.82 AR (1.00) LMNASHBGHSD17B10SERPINA6TSHR
Epitestosterone SCHEMBL21957465 0.82 AR (1.00) LMNASHBGHSD17B10SERPINA6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117660378-A Cytochrome P450 oxidase, genetic engineering strain thereof and application thereof 沈阳博泰生物制药有限公司 2024-03-08 CN claimed
US-20170360673-A1 HAIR COMPOSITION CONOPCO, INC., D/B/A UNILEVER (US) 2017-12-21 US claimed
EP-3236927-A1 HAIR COMPOSITION Unilever PLC (GB) 2017-11-01 EP claimed
WO-2016102177-A1 HAIR COMPOSITION UNILEVER PLC (GB) 2016-06-30 WO claimed
EP-2788088-A1 SKIN ANTI-AGEING COMPOSITION Unilever Plc. (GB) 2014-10-15 EP claimed
US-20140295010-A1 SKIN ANTI-AGEING COMPOSITION CONOPCO, INC. D/B/A UNILEVER (US) 2014-10-02 US claimed
WO-2013083431-A1 SKIN ANTI-AGEING COMPOSITION UNILEVER PLC (GB) 2013-06-13 WO claimed
EP-1432399-A1 ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN UNILEVER PLC (GB) 2004-06-30 EP claimed
US-20030124159-A1 Enhancing epidermal barrier development in skin UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC 2003-07-03 US claimed
WO-2003030857-A1 ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN UNILEVER PLC (GB) 2003-04-17 WO claimed
CN-117660378-A Cytochrome P450 oxidase, genetic engineering strain thereof and application thereof 沈阳博泰生物制药有限公司 2024-03-08 CN disclosed
US-11254924-B2 Method for biocatalysis using filamentous fungi THE UNIVERSITY OF THE WEST INDIES (JM) 2022-02-22 US disclosed
US-11254924-B2 Method for biocatalysis using filamentous fungi THE UNIVERSITY OF THE WEST INDIES (JM) 2022-02-22 US disclosed
CN-107106628-B Hair composition 荷兰联合利华有限公司 2021-01-12 CN disclosed
US-10456344-B2 Hair composition CONOPCO, INC. (US) 2019-10-29 US disclosed
WO-2004104143-A1 NITROGEN REJECTION FROM CONDENSED NATURAL GAS AIR PRODUCTS AND CHEMICALS, INC. (US) 2004-12-02 WO disclosed
WO-2004103376-A2 SKIN TREATMENTS UNILEVER PLC (GB) 2004-12-02 WO disclosed
EP-1432399-A1 ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN UNILEVER PLC (GB) 2004-06-30 EP disclosed
US-20030124159-A1 Enhancing epidermal barrier development in skin UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC 2003-07-03 US disclosed
WO-2003030857-A1 ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN UNILEVER PLC (GB) 2003-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030124159-A1 Enhancing epidermal barrier development in skin NR1H2, NR1H3, RXRB LMNA 1129/4885SHBG 1340/4885HSD17B10 760/4885
US-10456344-B2 Hair composition GLS2, GLS, LHCGR LMNA 1277/4885SHBG 42/4885HSD17B10 321/4885
US-20170360673-A1 HAIR COMPOSITION GLS2, GLS, CYP17A1 LMNA 1391/4885SHBG 43/4885HSD17B10 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.